Each week, The Fly will announce the newest downgrades to Strong Sell in StockNews.com's POWR Ratings algorithmic model.

This Fly exclusive recap identifies stocks with over a $1B market capitalization that have been downgraded this week to the Strong Sell, or "F," rating in the service's proprietary model that analyzes 118 different factors, each of which contribute a little to the stock's predicted likelihood of underperformance. A bell curve distribution of StockNews.com's ratings shows that only the top 5% of the over 5,000 stocks rated by the system are assigned a "Strong Buy," or "A," rating while the bottom 5% are assigned a Strong Sell. The F-rated stocks would have tumbled an average of 18.98% a year since 1999, according to StockNews.com.

This week's downgrades to Strong Sell as determined by the POWR Ratings algorithm: 

• Vacasa (VCSA) - operator of what the company touts as "the leading vacation rental management platform in North America"
• NeoGenomics (NEO) - a provider of cancer-focused genetic testing services and global oncology contract research services
  
• NexGen Energy (NXE) - a corporation focused on the development of the Rook I uranium project located in Saskatchewan, Canada into production
  
• Enovix (ENVX) - a company engaged in the design and manufacture of next generation silicon-anode lithium-ion batteries
  
• Sana Biotechnology (SANA) - a company whose hypoimmune platform seeks to create cells ex vivo that can “hide” from the patient’s immune system to enable the transplant of allogeneic cells without the need for immunosuppression
  
• Planet Labs PBC (PL) - a provider of satellite imagery and geospatial solutions that designs, builds, and operates what it touts as "the largest Earth observation fleet of imaging satellites"
  
• Recursion (RXRX) - a clinical-stage biotechnology company that says it is "industrializing drug discovery by decoding biology" with its Recursion Operating System platform that leverages machine-learning algorithms to generate a collection of hundreds of billions of searchable relationships across biology and chemistry
  
• Warby Parker (WRBY) - a direct-to-consumer lifestyle brand that designs products and develops technologies that help people see, including prescription glasses and contacts
  
• Lightspeed Commerce (LSPD) - a software and hardware developer that operates a commerce platform that serves retail, hospitality and golf businesses
  
• monday.com (MNDY) - operator of a "work operating system" platform, Work OS, that enables organizations to build work management tools and software applications
  
• PAR Technology (PAR) - a provider of restaurant hardware, software, drive-thru, and back-office solutions
  
• Energy Fuels (UUUU) - a U.S.-based uranium mining company that supplies major nuclear utilities
  
• Iveric Bio (ISEE) - a biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs
  

Learn more about the POWR Ratings

The Fly's recent reporting on these stocks includes: 

On July 28, Enovix Corporation announced an agreement with EDOM Technology, which has 32 sales offices across their subsidiary network in China, Singapore, Thailand, Vietnam, India, Malaysia, South Korea and Japan. "EDOM has more than 160 engineers that work directly with customers to design leading-edge, consumer-based products. The team includes technical experts with in-depth knowledge of the complexities of powering consumer electronics, who will work with targeted customers in Asia for Enovix," the company stated.

The same day, Canaccord analyst Katie Lachapelle initiated coverage of Energy Fuels with a Speculative Buy rating and C$10 price target. The company, a leading U.S. producer of uranium and vanadium and an emerging producer of rare earth element products, is leveraging its diverse asset base, including the White Mesa mill, on a path to become "a leading multi-commodity critical mineral company," Lachapelle said. Both uranium and rare earths have strong fundamental outlooks backed by the global energy transition and Energy Fuels is well positioned as "a proven producer with near-term production potential," the analyst added.

On July 26, Iveric Bio reported on its second quarter results. As of June 30, the company had $312M in cash, cash equivalents and available for sale securities. "We are excited to share that today marks one year since we completed patient enrollment of GATHER2, our second Phase 3 clinical trial for Zimura, a novel complement C5 inhibitor, for the treatment of geographic atrophy. Our team executed well all year as we exceeded our expectations for patient retention and injection fidelity, which we believe further de-risks GATHER2 and is an integral part of the clinical trial outcome. We look forward to reporting the topline data of GATHER2 in September of this year," stated Glenn Sblendorio, CEO of Iveric Bio.